What is ATTO's market cap?

$687.05M, based on the Nov 2 close of $15.05.

How much of ATTO is sold short?

1.5M shares, 5.6% of float, as of Oct 15, 2026.

What sector is ATTO in?

Healthcare, in the Biotechnology industry.

NASDAQ · ATTOHealthcareBiotechnology

Attovia Therapeutics, Inc. Common Stock (ATTO)

$15.05−0.92%

Close Nov 2, 2026 · split-adjusted

Oct 30, 2026$15.19▼ 33.35% in range

Sep 11, 2026Low $13.73 · High $24.52Oct 30, 2026

What changed · written from our data

As of Nov 2, 2026

Attovia Therapeutics closed at $15.05 on Nov 2, down 0.92%, 38.6% below its highest close since Sep 28. Volume of 154.9K shares was 0.40× its 20-day average (below normal).

Split-adjusted performance: -12.3% over one month.

Short interest was 1.5M shares at the Oct 15 settlement, down 11.9% from the prior report (5.6% of float, 3.5 days to cover).

Market cap$687.1M45.7M shares

Revenue · quarter——

Diluted EPS——

P/E · TTM—

Net margin—

Dividend yieldNone$0.34 last paid

Range since Sep 2813.73 – 24.52−38.6% from high

Volume154.9K0.40× 20-day avg

Volatility · 60d—Annualised

Short % of float5.6%3.5 days to cover

Net cash—

Next earnings—Not scheduled

Split-adjusted performance

1W +8.4%1M −12.3%3M —6M —YTD —1Y —3Y —5Y −44.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size68

Industry medians: 6-month return −22.5%, revenue growth +8.6%, net margin −271.3%, P/E 20.1×.

Short interest

Details →

Shares short1.5M−11.9% vs prior

Days to cover3.5Settled Oct 15

% of float5.6%

Short vol. 10d49.7%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ATTOAttovia Therapeutics	$15.05	−0.92%	—	—	—	—	$687.1M
DNAGinkgo Bioworks Holdings	$9.85	−12.13%	−0.6%	−48.5%	−231.7%	—	$663.3M	Compare
SANASana Biotechnology	$2.40	−6.61%	−29.6%	—	—	—	$718.5M	Compare
SLDBSolid Biosciences	$6.00	−3.23%	−17.0%	—	—	—	$643.4M	Compare
FDMT4D Molecular Therapeutics	$11.37	−4.45%	+20.4%	+25106.7%	−1929.0%	—	$628.1M	Compare
AURAAura Biosciences	$6.03	−1.79%	−27.8%	—	—	—	$625.3M	Compare
CADLCandel Therapeutics	$8.12	−2.52%	+7.8%	—	—	—	$621.3M	Compare
PRMEPrime Medicine	$4.44	−5.93%	+28.0%	+3.5%	−3649.0%	—	$805.3M	Compare
ENTXEntera Bio	$3.09	−3.44%	+178.4%	—	—	—	$537.4M	Compare

News about Attovia Therapeutics

All news →

No recent articles focused on Attovia Therapeutics.

Quick answers

What does Attovia Therapeutics do?: Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD).
What is ATTO's market cap?: $687.05M, based on the Nov 2 close of $15.05.
How much of ATTO is sold short?: 1.5M shares, 5.6% of float, as of Oct 15, 2026.
What sector is ATTO in?: Healthcare, in the Biotechnology industry.

About Attovia Therapeutics

Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.

HQ: San Carlos, CAListed Aug 5, 2026attovia.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology